EE146 Cost-Effectiveness of Axicabtagene Ciloleucel Versus Other CAR T-Cell Therapies in the Treatment of Diffuse Large B-Cell Lymphoma in France
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.398
https://www.valueinhealthjournal.com/article/S1098-3015(22)02602-X/fulltext
Title :
EE146 Cost-Effectiveness of Axicabtagene Ciloleucel Versus Other CAR T-Cell Therapies in the Treatment of Diffuse Large B-Cell Lymphoma in France
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02602-X&doi=10.1016/j.jval.2022.09.398
First page :
Section Title :
Open access? :
No
Section Order :
12204